Charles River Laboratories Corp.
This article was originally published in The Gray Sheet
Executive Summary
Initial public offering of up to $230 mil. in common stock by the former Bausch & Lomb business is outlined in an April 25 filing with the Securities and Exchange Commission. The Wilmington, Massachusetts provider of research animals and services for drug discovery is 73.6% owned by DLJ Merchant Banking Partners II following a Sept. 29 B&L divestiture; B&L retains 12.5% and current management the rest. Net proceeds to the stand-alone company will be used primarily for debt repayment. The number of shares and price per share have not yet been determined. CRLC sales for the year ended Dec. 25 increased 13.4% to $219.3 mil. Net income of $17.1 mil. was down 26.8%. Underwriters include Donaldson Lufkin & Jenrette Securities, Lehman Brothers, ING Barings, SG Cowen Securities, U.S. Bancorp Piper Jaffray, and DLJdirect, Inc
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.